Report Library
All Reports
Datamonitor Oncology Pathways in the US - Friend or Foe for Pharma
February 29, 2016
Datamonitor's independent research and analysis
provides extensive coverage of major disease areas, companies and strategic issues,
giving you the perspective to identify opportunities and threats arising from shifting market dynamics and the insights to
respond with faster, more effective decision-making. This strategy report focuses on Oncology Pathways in the US including management
of
oncology costs, oncology clinical pathway programs and developers, impact of pathways on oncology, and the future of oncology
pathways.
Highlights
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- A minority of US payers have implemented oncology pathways, but many expect use to increase.
- Research and company-reported data suggest that pathways help standardize treatment and save money in oncology.
- Oncology pathway inclusion will increasingly hinge on available biomarkers.
- Off-pathway and “ahead-of-pathway” messaging can drive success at the margins.
- Oncology medical societies will help drive pathways to progress in the private and potentially the public sector.
- Pathways will enter public sector payment models as components of larger APMs.
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Oncology |
| Indications Covered: | Castleman's Disease |
Additional Resources: